Abstract
We present the case of an elderly man with a small-joint polyarthritis, accompanied by pitting oedema, involving hands and feet, raising clinical suspicion of remitting seronegative symmetrical synovitis with pitting oedema (RS3PE). Treatment with corticosteroids was initiated with significant improvement, but unacceptable iatrogeny ensued, and tapering was not possible without disease flare-up. A trial of tocilizumab allowed disease activity control, slow weaning of corticosteroids and, ultimately, its suspension. RS3PE is a rare rheumatological entity, initially thought to be a variant of rheumatoid arthritis (RA), with shared traits with polymyalgia rheumatica (PMR), and other seronegative spondyloarthropathies, thereby implying a shared pathophysiological background. Elevated levels of interleukin 6 (IL-6) are found in patients with RA, have shown to mirror disease activity in PMR and have also been described in the serum and synovial fluid of patients with RS3PE. Tocilizumab, an anti-IL-6 receptor antibody, shows auspicious results in several other rare rheumatic diseases other than RA.
Reference21 articles.
1. Remitting Seronegative Symmetrical Synovitis With Pitting Edema
2. The clinical spectrum of remitting seronegative symmetrical synovitis with pitting edema. The Catalan group for the study of Rs3Pe;Olivé;J Rheumatol,1997
3. Paraneoplastic remitting seronegative symmetrical synovitis with pitting edema;Cantini;Clin Exp Rheumatol,1999
4. Remitting seronegative symmetrical synovitis with pitting oedema: a study of 12 cases;Paira;Clin Rheumatol,2002
5. Is Remitting Seronegative Symmetrical Synovitis with Pitting Edema (RS3PE) a Subset of Rheumatoid Arthritis?